Marvel Biosciences priced its units at 15 cents and asked investors for up to $3 million. It closed with $1.6 million, after a first closing originally expected around August 14 slid to the end of September. The money pays the deposit on a trial the company once expected to begin in the second quarter.
Marvel Biosciences Closes $1.6 Million of a Planned $3 Million Raise
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) closed its non-brokered private placement on September 29, issuing 10,654,298 units at $0.15 each for gross proceeds of $1,598,144.70. That works out to about 53% of the $3 million maximum, and roughly $98,000 above the $1.5 million minimum Marvel set when it announced the offering on July 16.
Most of the money has a named destination. According to the company, net proceeds will pay a deposit for the Phase 1 clinical trial of MB-204, its lead compound, with what remains going to overhead and working capital. Phase 1 is the first stage of human testing; it checks safety and how a drug behaves in the body, not whether it treats a disease. The release does not say how large the deposit is.
The release headline still reads “For Up To $3.0 Million.” The number in the body is $1.6 million.
The September 29 release announces no further tranche, and it does not say whether any directors or officers bought units.
Marvel Units Carry $0.20 Warrants With a $0.25 Acceleration Clause
Each unit pairs one common share with one warrant to buy another share at $0.20. Warrants become exercisable on the 61st day after closing and run for one year from the closing date. There is a catch for holders. If the stock’s volume-weighted average price (VWAP, the average trading price weighted by the number of shares traded) holds at $0.25 or higher for five consecutive trading days after that 61-day mark, Marvel can accelerate expiry to as little as 30 days after notice.
If every investor warrant were exercised, Marvel would collect about $2.13 million more and issue another 10,654,298 shares. That figure is aktiego.com’s arithmetic from the disclosed terms, not a company projection.
Finders were paid $77,175.49 in cash and 494,737 finder’s warrants. Six dealers acted as finders, Raymond James and Canaccord Genuity among them.
The units were sold under Canada’s listed issuer financing exemption, which lets an already-listed company raise capital using a short offering document rather than a full prospectus. Shares sold this way carry no hold period. They can trade right away.
MB-204 Phase 1 Deposit Comes After a Q2 2026 Start Target
MB-204 is a fluorinated version of istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker on the market. Marvel is developing it for Rett syndrome and Fragile X syndrome, and the company has also named autism spectrum disorder and depression as potential targets. MB-204 is investigational. It has not been approved anywhere for any use.
The timeline has moved. In an April 7 release, Marvel said the Phase 1 trial was expected to commence in Q2 2026, testing the drug’s safety and pharmacokinetics (how the body absorbs and clears a drug) in healthy volunteers. The second quarter ended June 30. No announcement of a trial start or first dosing turned up in the sources reviewed for this article, and Marvel has not published a revised start date.
That same release described support from 5 Horizons Ventures equal to 15% of the trial’s costs at Novotech, the contract research organization (CRO), meaning the outside firm hired to run the study. Marvel called the support non-dilutive. In March, it also announced a $600,000 project funded through Alberta Innovates toward Phase 1 testing.
Marvel says that in animal models, MB-204 improved social and behavioral deficits and, on certain endpoints, outperformed the only approved Rett syndrome therapy. That is the company’s own characterization of preclinical animal work. No human efficacy data exist yet. The company has also said it is pursuing Orphan Drug Designation from the FDA, a status that gives incentives to drugs for rare diseases; no designation has been announced, and a designation would not mean approval.
Marvel Added a $500,000 Convertible Debenture in April
September’s units were not the year’s first raise. On April 17, Marvel closed $500,000 in unsecured convertible debentures, loans the holder can swap for stock, carrying 12% annual interest and maturing December 31, 2027. The conversion price is $0.17 a share. At that price the full principal would convert into roughly 2.94 million shares, and Marvel may pay the interest in shares rather than cash.
The April money was slated for drug formulation and toxicology studies, among other uses.
Marvel’s current cash balance and quarterly burn were not identified in the sources reviewed. The September 29 release does not state the share count after closing, so the percentage dilution from the new units cannot be calculated from it. The company points investors to its September 16 offering document and its SEDAR+ filings.
Marvel Biosciences Warrant and Debenture Dates Through 2027
The September warrants become exercisable 61 days after the September 29 closing, in late November 2026, and expire on September 29, 2027. The April debentures mature on December 31, 2027. Marvel has not disclosed a revised start date for the MB-204 Phase 1 trial.
Sources
- Newsfile: Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million, September 29, 2026
- Newsfile: Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million, September 17, 2026
- Marvel Biosciences (company website): Marvel Biosciences Announces Private Placement Up to $3 Million, July 16, 2026
- Newsfile: Marvel Biosciences Announces Closing of Convertible Debenture Offering, April 17, 2026
- GlobeNewswire: Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures, April 7, 2026
- GlobeNewswire: Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204, March 30, 2026
Editorial Disclosure
This article is based entirely on publicly available information, principally Marvel Biosciences’ own press releases distributed via Newsfile and GlobeNewswire and posted on the company’s website. The security discussed is Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF). aktiego.com has not received any compensation from Marvel Biosciences, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in this security at the time of publication.
The private placement issued 10,654,298 new shares plus an equal number of warrants exercisable at $0.20. Finders received another 494,737 warrants. All of it is dilutive to existing shareholders. Shares issued under the listed issuer financing exemption carry no hold period. The $500,000 of convertible debentures closed in April 2026 convert at $0.17 per share, and interest on them may be paid in shares. The release headline refers to a placement of up to $3.0 million; gross proceeds actually raised were $1,598,144.70.
MB-204 is a preclinical-stage investigational compound and has not been approved by Health Canada, the FDA, or any other regulator for any indication. Statements comparing MB-204 favorably with an approved Rett syndrome therapy are the company’s own characterization of animal studies, not human clinical data. Orphan Drug Designation is, per the company, being pursued; none has been announced as granted, and a designation would not indicate or guarantee approval. Marvel said in April 2026 that Phase 1 was expected to begin in Q2 2026. No announcement of a Phase 1 start was identified in the sources reviewed, and no revised timeline has been disclosed.
No specific cash balance or cash runway was identified in the sources reviewed. Neither was any going-concern language; readers should consult the company’s financial statements on SEDAR+. Whether insiders participated in the September placement is not disclosed in the closing release. Potential warrant-exercise proceeds cited here are aktiego.com’s own calculation from disclosed terms and depend entirely on holders choosing to exercise. Funding from 5 Horizons Ventures and Alberta Innovates is reported as described in the company’s releases and has not been independently verified. Per the company’s own standard disclosure, neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of Marvel’s press releases.
Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER
